Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
(ANTX) stock logo
ANTX
(ANTX)
$1.27
+3.7%
$0.00
$0.87
$3.07
$33.76M0.15341,215 shs83,337 shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$2.11
-4.1%
$1.76
$1.31
$8.33
$149.72M0.831.09 million shs455,993 shs
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
$2.76
-1.4%
$1.62
$0.83
$2.90
$182.83M1.03700,609 shs898,023 shs
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
$1.36
-5.6%
$1.14
$0.54
$1.91
$158.91M0.54449,646 shs349,040 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
(ANTX) stock logo
ANTX
(ANTX)
0.00%+0.80%-12.09%+0.80%-47.29%
Nkarta, Inc. stock logo
NKTX
Nkarta
0.00%+16.57%+7.11%-15.26%-70.57%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
0.00%+33.98%+84.00%+122.58%+24.32%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00%+27.10%+19.30%+71.70%+72.13%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
2.7581 of 5 stars
3.63.00.00.03.01.70.6
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3.5203 of 5 stars
3.55.00.00.04.03.30.0
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.5923 of 5 stars
0.03.00.00.02.21.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
(ANTX) stock logo
ANTX
(ANTX)
2.00
Hold$2.67110.80% Upside
Nkarta, Inc. stock logo
NKTX
Nkarta
3.25
Buy$14.86604.13% Upside
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3.00
Buy$12.75361.96% Upside
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ANTX, RGLS, TLSA, and NKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/27/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
3/27/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
3/27/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$11.00 ➝ $11.00
3/27/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeEqual Weight ➝ Overweight$3.00 ➝ $6.00
3/17/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00 ➝ $28.00
3/14/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/26/2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/3/2025
(ANTX) stock logo
ANTX
(ANTX)
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$5.00 ➝ $5.00
(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/A$4.19 per shareN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$5.56 per shareN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/A$1.05 per shareN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/A$0.05 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
(ANTX) stock logo
ANTX
(ANTX)
-$64.73M-$2.04N/AN/AN/AN/A-57.62%-52.08%N/A
Nkarta, Inc. stock logo
NKTX
Nkarta
-$117.50M-$1.66N/AN/AN/AN/A-27.13%-21.67%5/8/2025 (Estimated)
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$30.04M-$0.87N/AN/AN/AN/A-53.07%-48.58%5/8/2025 (Estimated)
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
-$17.69MN/A0.00N/AN/AN/AN/AN/A

Latest ANTX, RGLS, TLSA, and NKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.45N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.33N/AN/AN/AN/AN/A
3/26/2025Q4 2024
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.41-$0.35+$0.06-$0.35N/AN/A
3/20/2025Q4 2024
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
-$0.20-$0.20N/A-$0.20N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
(ANTX) stock logo
ANTX
(ANTX)
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/AN/AN/AN/AN/A
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
(ANTX) stock logo
ANTX
(ANTX)
N/A
9.75
9.75
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
12.91
12.91
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
N/A
14.15
14.14
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A
0.85
N/A

Institutional Ownership

CompanyInstitutional Ownership
(ANTX) stock logo
ANTX
(ANTX)
90.47%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
92.38%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
N/A

Insider Ownership

CompanyInsider Ownership
(ANTX) stock logo
ANTX
(ANTX)
20.79%
Nkarta, Inc. stock logo
NKTX
Nkarta
8.70%
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
4.35%
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
39.82%
CompanyEmployeesShares OutstandingFree FloatOptionable
(ANTX) stock logo
ANTX
(ANTX)
N/A29.88 million23.67 millionNot Optionable
Nkarta, Inc. stock logo
NKTX
Nkarta
14070.96 million64.43 millionOptionable
Regulus Therapeutics Inc. stock logo
RGLS
Regulus Therapeutics
3066.24 million62.65 millionOptionable
Tiziana Life Sciences Ltd stock logo
TLSA
Tiziana Life Sciences
8116.85 million63.43 millionOptionable

Recent News About These Companies

Tiziana submits FDA investigational new drug application
Tiziana Life Sciences expects to complete Long Covid study in Q2

New MarketBeat Followers Over Time

Media Sentiment Over Time

(ANTX) stock logo

(ANTX) NYSE:ANTX

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$2.11 -0.09 (-4.09%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$2.12 +0.01 (+0.52%)
As of 04/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Regulus Therapeutics stock logo

Regulus Therapeutics NASDAQ:RGLS

$2.76 -0.04 (-1.43%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$2.76 0.00 (0.00%)
As of 04/25/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Tiziana Life Sciences stock logo

Tiziana Life Sciences NASDAQ:TLSA

$1.36 -0.08 (-5.56%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.32 -0.05 (-3.31%)
As of 04/25/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.